Skip to content

Cognitive stimulation therapy for elderly with cognitive and functional complaints: Brazilian adaptation and validation

Cognitive stimulation therapy for Dementia: Brazilian adaptation and validation

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-3r6pc2
Enrollment
Unknown
Registered
2017-07-17
Start date
2017-07-01
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

central nervous disease

Interventions

Cognitive stimulation therapy 50 participants over 60 years of age diagnosed with dementia will be randomized into two groups. Intervention group: 25 elderly people with dementia will be distributed i
Control group: 25 elderly people with dementia will receive the usual treatment, which is the recommended drug treatment for dementia and Regular medical visits at the discretion of the attending phys
Other

Sponsors

Pontifícia Universidade Católica do Rio de Janeiro
Lead Sponsor
Pontifícia Universidade Católica do Rio de Janeiro
Collaborator
Instituto de Psiquiatria da Universidade Federal do Rio de Janeiro
Collaborator

Eligibility

Age
60 Years to 95 Years

Inclusion criteria

Inclusion criteria: Age over 60 years; Both genders; People diagnosed with dementia; Score between 10 and 24 on the Mini Mental State Exam; Be able to answer neuropsychological evaluation.

Exclusion criteria

Exclusion criteria: Age greater than 95 years. Mental retardation previously diagnosed according to ICD criteria 10.

Design outcomes

Primary

MeasureTime frame
The primary endpoint is enhancement in cognition, as measured by the Cognitive Alzheimer's Disease Assessment (ADAS-Cog) scale. ADAS-Cog uses 11 tasks to measure cognitive domains, such as memory, praxis, and language. The differences in the responses found in the scales applied at the beginning and at the end of the study will be evaluated through statistical analysis using 2X2 ANOVA. Considering that this is a validation study, the analyzes will be exploratory. The scales will be applied within two weeks before the start of the study and within one week after the end of the study.

Secondary

MeasureTime frame
Secondary outcomes include imporbvement in quality of life as measured by QoL-AD scale, imporvement in depressive symptoms as measured by Cornell Scale for Depression in Dementia (CSDD), imporvement in disease awareness as measured by ASPIDD scale and reduction in caregiver bruden as measured by Zarit Burden Scale (ZBI). The differences in the responses found in the scales applied at the beginning and at the end of the study will be evaluated. The scales will be applied within two weeks before the start of the study and within one week after the end of the study.

Countries

Brazil

Contacts

Public ContactDaniel Mograbi

Pontifícia Universidade Católica do Rio de Janeiro

danielmograbi@puc-rio.br(55 21) 3527-1001

Outcome results

None listed

Source: REBEC (via WHO ICTRP)